Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia

BOSTAN H. , TOPTAŞ T. , Tanrikulu F. P. , Kut K., Arikan F., Yilmaz F., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.20, no.12, pp.836-842, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 12
  • Publication Date: 2020
  • Doi Number: 10.1016/j.clml.2020.08.009
  • Page Numbers: pp.836-842


We assessed the quality of life and symptom burden in patients with chronic-phase chronic myeloid leukemia (CML) receiving first- or second-generation tyrosine kinase inhibitors, to demonstrate whether there are differences between tyrosine kinase inhibitor generations. A total of 121 patients with CML with good performance and low comorbidity scores were enrolled in the study. Similar results were observed between the groups in the quality of life and symptom burden scores, which were examined using CML-specific (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chronic Myeloid Leukemia module, MD Anderson Symptom Inventory for Chronic Myeloid Leukemia) questionnaires.